Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Other Non-Current Liabilities (2021 - 2023)

Inmune Bio (INMB) has disclosed Other Non-Current Liabilities for 3 consecutive years, with $804000.0 as the latest value for Q3 2023.

  • Quarterly Other Non-Current Liabilities changed N/A to $804000.0 in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $804000.0 through Sep 2023, changed N/A year-over-year, with the annual reading at $550000.0 for FY2022, N/A changed from the prior year.
  • Other Non-Current Liabilities hit $804000.0 in Q3 2023 for Inmune Bio, up from $550000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $804000.0 in Q3 2023 to a low of $160000.0 in Q2 2021.
  • Historically, Other Non-Current Liabilities has averaged $439500.0 across 3 years, with a median of $397000.0 in 2021.